John W. Wizeman, Ph.D.

Dr. John Wizeman is a technical specialist in the Lathrop GPM Intellectual Property practice, focusing his efforts on biotechnology and life sciences.

John has been working at Lathrop GPM for four years, with a focus on antibodies and fusion proteins, including bispecific/multispecific antibodies and chimeric extended half-life fusion proteins. John has experience in multi-jurisdictional portfolio management, including SPC protection. In addition, John was a postdoctoral researcher at the University of Connecticut Health Center where he designed and conducted single-cell RNA sequencing experiments and led analysis of results using groundbreaking programming tools and developing analytical pipelines in the neuroscience field.